Phospho-CHEK1 (Ser286) Antibody

What is the biological significance of CHEK1 protein and its phosphorylation at Ser286?

CHEK1 (Checkpoint Kinase 1) is a serine/threonine protein kinase that plays a critical role in the DNA damage response pathway and cell cycle checkpoint regulation. It belongs to the Ser/Thr protein kinase family and is required for checkpoint-mediated cell cycle arrest in response to DNA damage or the presence of unreplicated DNA .

How does CHEK1 function in the DNA damage response network?

CHEK1 serves as a critical "messenger" in the DNA damage response network through multiple mechanisms:

• Signal integration: CHEK1 integrates signals from ATM and ATR, two cell cycle proteins involved in DNA damage responses .

• Cell cycle arrest: Upon activation, CHEK1 phosphorylates multiple downstream targets including CDC25A, CDC25B, and CDC25C phosphatases . This phosphorylation creates binding sites for 14-3-3 proteins, leading to inhibition of these phosphatases and subsequent cell cycle arrest .

• DNA repair facilitation: CHEK1 promotes DNA repair through interactions with RAD51, facilitating homologous recombination repair .

• Genome integrity maintenance: CHEK1 helps preserve genome integrity through multiple mechanisms including replication fork maintenance and transcriptional regulation of cell cycle-related genes .

What are the specific properties of Phospho-CHEK1 (Ser286) Antibody?

What is the recommended protocol for using Phospho-CHEK1 (Ser286) Antibody in Western Blot analysis?

Protocol for Western Blot Analysis:

• Sample preparation:

  • Harvest cells and lyse in appropriate buffer containing phosphatase inhibitors

  • Use fresh samples or snap-freeze immediately to preserve phosphorylation status

  • Quantify protein concentration using Bradford or BCA assay

• Gel electrophoresis and transfer:

  • Load 20-50 μg of protein per lane

  • Separate proteins using 10% SDS-PAGE

  • Transfer to PVDF or nitrocellulose membrane (0.45 μm pore size recommended)

• Blocking and antibody incubation:

  • Block in 5% BSA in TBST for 1 hour at room temperature

  • Incubate with Phospho-CHEK1 (Ser286) Antibody at 1:500-1:2000 dilution overnight at 4°C

  • Wash 3 times with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

  • Wash 3 times with TBST, 5 minutes each

• Detection:

  • Apply ECL substrate and detect signal using film or digital imaging system

  • Expected molecular weight: 54-56 kDa

• Controls:

  • Positive control: Cells treated with serum or growth factors

  • Negative control: Samples treated with phosphatase

  • Specificity control: Pre-incubation of antibody with phosphopeptide should abolish signal

How can I optimize immunofluorescence experiments using Phospho-CHEK1 (Ser286) Antibody?

Immunofluorescence Optimization Protocol:

• Sample preparation:

  • Grow cells on coverslips in 6-well plates

  • Treat cells as needed to induce CHEK1 phosphorylation

  • Fix cells in 4% formaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 in PBS for 10 minutes

• Blocking and antibody incubation:

  • Block in 5% normal goat serum in PBS for 1 hour at room temperature

  • Incubate with Phospho-CHEK1 (Ser286) Antibody at 1:200-1:1000 dilution for 2 hours at room temperature or overnight at 4°C

  • Wash 3 times with PBS, 5 minutes each

  • Incubate with fluorophore-conjugated secondary antibody (Alexa Fluor 488 or 568) for 1 hour at room temperature

  • Wash 3 times with PBS, 5 minutes each

  • Counterstain nuclei with DAPI and mount using appropriate medium

• Imaging considerations:

  • CHEK1 may be detected in both nuclear and cytoplasmic compartments depending on phosphorylation status

  • Co-staining with total CHEK1 antibody can help assess the proportion of phosphorylated CHEK1

  • Use confocal microscopy for better resolution of subcellular localization

How should I validate the specificity of Phospho-CHEK1 (Ser286) Antibody?

Validation strategies include:

• Peptide competition assay:

  • Pre-incubate antibody with phosphorylated peptide (containing p-Ser286) and non-phosphorylated peptide separately

  • Signal should be abolished with phosphopeptide but not with non-phosphorylated peptide

• Phosphatase treatment:

  • Treat half of your sample with lambda phosphatase

  • Signal should decrease or disappear in treated samples

• Genetic approaches:

  • Use CHEK1 knockout cells as negative control

  • Generate S286A mutant (non-phosphorylatable) and compare with wild-type CHEK1

  • Signal should be absent in S286A mutant-expressing cells

• Cross-validation with other antibodies:

  • Compare results with antibodies from different vendors or clones

  • Confirm with mass spectrometry if possible for absolute validation

How does Ser286 phosphorylation compare to other CHEK1 phosphorylation sites?

CHEK1 undergoes phosphorylation at multiple sites with different functional consequences:

Unlike the well-characterized Ser317/345 phosphorylation by ATR in response to DNA damage and Ser280 phosphorylation by AKT/p90 RSK in response to growth factors, the kinase responsible for Ser286 phosphorylation and its precise function remain less documented in the literature. This represents an opportunity for novel research contributions.

What experimental conditions promote CHEK1 Ser286 phosphorylation?

Based on research with other CHEK1 phosphorylation sites, the following conditions may be used to study Ser286 phosphorylation:

• DNA damage induction:

  • UV irradiation (10-50 J/m²)

  • Ionizing radiation (2-10 Gy)

  • Topoisomerase inhibitors: etoposide (10-50 μM, 1-24 hours)

  • Replication stress: hydroxyurea (1-2 mM, 6-24 hours)

• Growth factor stimulation:

  • Serum stimulation (10% FBS after serum starvation)

  • Insulin or IGF-1 treatment (activates PI3K/AKT pathway)

• Cell cycle synchronization:

  • Monitor changes in Ser286 phosphorylation across different cell cycle phases

  • Thymidine block-release or nocodazole synchronization protocols

How can I quantitatively assess changes in CHEK1 Ser286 phosphorylation?

Quantitative assessment methods:

• Western blot quantification:

  • Always normalize phospho-signal to total CHEK1 levels

  • Use image analysis software (ImageJ, LI-COR, etc.) for densitometry

  • Include standard curves for accurate quantification

• Phos-tag SDS-PAGE:

  • This technique separates phosphorylated from non-phosphorylated proteins

  • Allows for assessment of the proportion of CHEK1 molecules phosphorylated at various sites

  • Combine with Western blotting using total CHEK1 antibody

• Flow cytometry:

  • Particularly useful for assessing phosphorylation in different cell populations

  • Allows correlation with cell cycle phases using DNA content markers

• Phosphoproteomics:

  • Mass spectrometry-based approaches for absolute quantification

  • Can detect multiple phosphorylation sites simultaneously

  • Consider enrichment strategies (e.g., phosphopeptide enrichment) for low-abundance modifications

How can I troubleshoot weak or absent signals when detecting phospho-CHEK1 (Ser286)?

Common issues and solutions:

• Low phosphorylation level:

  • Ensure appropriate stimulation to induce phosphorylation

  • Reduce time between cell treatment and lysis

  • Enrich for phosphorylated proteins using phospho-protein enrichment kits

• Phosphorylation loss during sample preparation:

  • Always include phosphatase inhibitors in lysis buffers

  • Keep samples cold at all times

  • Avoid repeated freeze-thaw cycles

  • Use fresh samples when possible

• Antibody-related issues:

  • Optimize antibody concentration (try 1:250 if signal is weak)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try different blocking agents (BSA vs. milk)

  • Note that milk contains phosphatases and should be avoided in phospho-protein detection

• Detection sensitivity:

  • Use high-sensitivity ECL substrate for Western blot

  • Consider signal amplification methods for immunofluorescence

  • Try alternative detection methods (e.g., biotin-streptavidin systems)

What are the important considerations when studying CHEK1 phosphorylation in different cellular compartments?

CHEK1 undergoes dynamic subcellular relocalization upon phosphorylation, which is an important aspect of its regulation:

• Subcellular fractionation techniques:

  • Separate nuclear, cytoplasmic, and chromatin-bound fractions

  • Use appropriate markers to confirm fraction purity (e.g., Lamin A/C for nuclear, GAPDH for cytoplasmic)

  • Analyze phospho-CHEK1 (Ser286) distribution across fractions by Western blot

• Localization dynamics:

  • Phosphorylated CHEK1 undergoes rapid release from damaged chromosomal sites into the soluble nucleoplasm and later into the cytoplasm

  • Different phosphorylation sites may affect localization differently

  • Time-course experiments are essential to capture these dynamics

• Protein interactions in different compartments:

  • Consider co-immunoprecipitation studies with compartment-specific markers

  • CHEK1 interacts with various proteins including Claspin, PCNA, and Tim/Tipin complex

  • These interactions may be phosphorylation-dependent

How does CHEK1 Ser286 phosphorylation potentially relate to cancer research and therapy?

CHEK1 has emerging significance in cancer biology and therapeutics:

• Role in cancer progression:

  • Evidence suggests CHEK1 is not a tumor suppressor but may promote tumor growth

  • CHEK1 overexpression is observed in various cancers

  • Monitoring Ser286 phosphorylation might provide insights into cancer-specific CHEK1 regulation

• CHEK1 inhibitors in cancer therapy:

  • Multiple CHEK1 inhibitors are in clinical development

  • Phosphorylation status at different sites may predict response to these inhibitors

  • Combining radiation or chemotherapy with CHEK1 inhibition may enhance therapeutic efficacy

• Biomarker potential:

  • Investigating whether Ser286 phosphorylation correlates with:

    • Cancer progression stages

    • Response to DNA-damaging therapies

    • Resistance mechanisms to standard treatments

• Experimental design for cancer studies:

  • Compare phosphorylation levels between cancer and normal tissues

  • Assess correlation with clinical outcomes

  • Evaluate changes before and after treatment with DNA-damaging agents

What are the unresolved questions regarding CHEK1 Ser286 phosphorylation?

Several key questions remain to be investigated:

• Regulatory kinase identification:

  • Which kinase(s) phosphorylate CHEK1 at Ser286?

  • Under what conditions is this phosphorylation induced?

• Functional consequences:

  • How does Ser286 phosphorylation affect CHEK1 kinase activity?

  • Does it influence protein stability, localization, or interactions?

  • What is the relationship between Ser286 and other phosphorylation sites?

• Pathway integration:

  • How does Ser286 phosphorylation integrate with other DNA damage response pathways?

  • Does it play a role in crosstalk between cell survival and apoptotic pathways?

What novel techniques might enhance the study of CHEK1 phosphorylation dynamics?

Emerging methodologies:

• Live-cell imaging:

  • Phospho-specific fluorescent biosensors for real-time monitoring

  • FRET-based approaches to study conformation changes upon phosphorylation

• Single-cell analysis:

  • Mass cytometry (CyTOF) for multi-parameter analysis of phosphorylation at single-cell level

  • Single-cell phosphoproteomics to capture heterogeneity in phosphorylation patterns

• Genome editing approaches:

  • CRISPR-Cas9 to create phosphomimetic (S286D/E) or phospho-dead (S286A) mutations

  • Site-specific incorporation of phosphoserine using expanded genetic code approaches

• Structural biology:

  • Cryo-EM or X-ray crystallography to determine how Ser286 phosphorylation affects CHEK1 structure

  • Molecular dynamics simulations to predict functional consequences